Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Era+ breast cancer patients often develop resistance to endocrine therapy. Here, the authors show that FGFR1 amplification is a resistance mechanism to CDK4/6 inhibitor and endocrine therapy and that combined treatment with FGFR, CDK4/6, and anti-estrogens is a potential therapeutic strategy in Era+...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Luigi Formisano, Yao Lu, Alberto Servetto, Ariella B. Hanker, Valerie M. Jansen, Joshua A. Bauer, Dhivya R. Sudhan, Angel L. Guerrero-Zotano, Sarah Croessmann, Yan Guo, Paula Gonzalez Ericsson, Kyung-min Lee, Mellissa J. Nixon, Luis J. Schwarz, Melinda E. Sanders, Teresa C. Dugger, Marcelo Rocha Cruz, Amir Behdad, Massimo Cristofanilli, Aditya Bardia, Joyce O’Shaughnessy, Rebecca J. Nagy, Richard B. Lanman, Nadia Solovieff, Wei He, Michelle Miller, Fei Su, Yu Shyr, Ingrid A. Mayer, Justin M. Balko, Carlos L. Arteaga
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/c9a8bb9c2aac44dba476758c76c4a8d4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c9a8bb9c2aac44dba476758c76c4a8d4
record_format	dspace
spelling	oai:doaj.org-article:c9a8bb9c2aac44dba476758c76c4a8d42021-12-02T15:35:50ZAberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer10.1038/s41467-019-09068-22041-1723https://doaj.org/article/c9a8bb9c2aac44dba476758c76c4a8d42019-03-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-09068-2https://doaj.org/toc/2041-1723Era+ breast cancer patients often develop resistance to endocrine therapy. Here, the authors show that FGFR1 amplification is a resistance mechanism to CDK4/6 inhibitor and endocrine therapy and that combined treatment with FGFR, CDK4/6, and anti-estrogens is a potential therapeutic strategy in Era+ breast cancer tumors.Luigi FormisanoYao LuAlberto ServettoAriella B. HankerValerie M. JansenJoshua A. BauerDhivya R. SudhanAngel L. Guerrero-ZotanoSarah CroessmannYan GuoPaula Gonzalez EricssonKyung-min LeeMellissa J. NixonLuis J. SchwarzMelinda E. SandersTeresa C. DuggerMarcelo Rocha CruzAmir BehdadMassimo CristofanilliAditya BardiaJoyce O’ShaughnessyRebecca J. NagyRichard B. LanmanNadia SolovieffWei HeMichelle MillerFei SuYu ShyrIngrid A. MayerJustin M. BalkoCarlos L. ArteagaNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-14 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Luigi Formisano Yao Lu Alberto Servetto Ariella B. Hanker Valerie M. Jansen Joshua A. Bauer Dhivya R. Sudhan Angel L. Guerrero-Zotano Sarah Croessmann Yan Guo Paula Gonzalez Ericsson Kyung-min Lee Mellissa J. Nixon Luis J. Schwarz Melinda E. Sanders Teresa C. Dugger Marcelo Rocha Cruz Amir Behdad Massimo Cristofanilli Aditya Bardia Joyce O’Shaughnessy Rebecca J. Nagy Richard B. Lanman Nadia Solovieff Wei He Michelle Miller Fei Su Yu Shyr Ingrid A. Mayer Justin M. Balko Carlos L. Arteaga Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
description	Era+ breast cancer patients often develop resistance to endocrine therapy. Here, the authors show that FGFR1 amplification is a resistance mechanism to CDK4/6 inhibitor and endocrine therapy and that combined treatment with FGFR, CDK4/6, and anti-estrogens is a potential therapeutic strategy in Era+ breast cancer tumors.
format	article
author	Luigi Formisano Yao Lu Alberto Servetto Ariella B. Hanker Valerie M. Jansen Joshua A. Bauer Dhivya R. Sudhan Angel L. Guerrero-Zotano Sarah Croessmann Yan Guo Paula Gonzalez Ericsson Kyung-min Lee Mellissa J. Nixon Luis J. Schwarz Melinda E. Sanders Teresa C. Dugger Marcelo Rocha Cruz Amir Behdad Massimo Cristofanilli Aditya Bardia Joyce O’Shaughnessy Rebecca J. Nagy Richard B. Lanman Nadia Solovieff Wei He Michelle Miller Fei Su Yu Shyr Ingrid A. Mayer Justin M. Balko Carlos L. Arteaga
author_facet	Luigi Formisano Yao Lu Alberto Servetto Ariella B. Hanker Valerie M. Jansen Joshua A. Bauer Dhivya R. Sudhan Angel L. Guerrero-Zotano Sarah Croessmann Yan Guo Paula Gonzalez Ericsson Kyung-min Lee Mellissa J. Nixon Luis J. Schwarz Melinda E. Sanders Teresa C. Dugger Marcelo Rocha Cruz Amir Behdad Massimo Cristofanilli Aditya Bardia Joyce O’Shaughnessy Rebecca J. Nagy Richard B. Lanman Nadia Solovieff Wei He Michelle Miller Fei Su Yu Shyr Ingrid A. Mayer Justin M. Balko Carlos L. Arteaga
author_sort	Luigi Formisano
title	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
title_short	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
title_full	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
title_fullStr	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
title_full_unstemmed	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
title_sort	aberrant fgfr signaling mediates resistance to cdk4/6 inhibitors in er+ breast cancer
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/c9a8bb9c2aac44dba476758c76c4a8d4
work_keys_str_mv	AT luigiformisano aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT yaolu aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT albertoservetto aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT ariellabhanker aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT valeriemjansen aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT joshuaabauer aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT dhivyarsudhan aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT angellguerrerozotano aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT sarahcroessmann aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT yanguo aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT paulagonzalezericsson aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT kyungminlee aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT mellissajnixon aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT luisjschwarz aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT melindaesanders aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT teresacdugger aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT marcelorochacruz aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT amirbehdad aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT massimocristofanilli aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT adityabardia aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT joyceoshaughnessy aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT rebeccajnagy aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT richardblanman aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT nadiasolovieff aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT weihe aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT michellemiller aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT feisu aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT yushyr aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT ingridamayer aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT justinmbalko aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer AT carloslarteaga aberrantfgfrsignalingmediatesresistancetocdk46inhibitorsinerbreastcancer
_version_	1718386439456030720

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Ejemplares similares